Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Manoj Motwani

Ophthalmology San Diego, CA Medical Doctor

NPI 1568887149 CMS profile 161780

4520 Executive Dr, Suite 230, San Diego, CA 92121

Open in the dashboard

General payments

$37,256

84 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Manoj Motwani of San Diego, CA is reported in the CMS Open Payments database as having received $37,256 across 84 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $756 28
2024 General $377 22
2023 General $244 9
2022 General $461 12
2021 General $35,039 3
2020 General $14 1
2019 General $364 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Manoj Motwani
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Manoj Motwani were reported at $756. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Manoj Motwani Ophthalmology median Middle half National median
2019 $364 $258 $104–$655 $163
2020 $14 $126 $45–$321 $114
2021 $35,039 $205 $76–$534 $132
2022 $461 $266 $100–$678 $149
2023 $244 $308 $117–$745 $160
2024 $377 $340 $127–$846 $164
2025 $756 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Optovue, Inc. $35,000 1 payment
  2. Oyster Point Pharma, Inc. $709 22 payments
  3. Bausch & Lomb Americas Inc. $542 30 payments
  4. Alcon Vision LLC $359 9 payments
  5. Novartis Pharmaceuticals Corporation $251 8 payments
  6. Shire North American Group Inc $185 5 payments
  7. Tarsus Pharmaceuticals, Inc. $70 3 payments
  8. Allergan Inc. $44 2 payments
  9. Harrow Eye, LLC $38 1 payment
  10. Beaver-Visitec International, Inc. $20 1 payment
  11. Other $37 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $35,000 1 payment
  2. Food and Beverage $2,256 83 payments
Products named General payments · program years 2019–2025
  1. Solix System $35,000 1 payment
  2. TYRVAYA Dry Eye $419 10 payments
  3. MIEBO $347 24 payments
  4. XIIDRA Ophthalmology $299 21 payments
  5. TRYPTYR $291 4 payments
  6. TYRVAYA Dry eyes $290 12 payments
  7. XIIDRA Ophthalmology $222 13 payments
  8. XIIDRA Opthalmics $185 5 payments
  9. XIIDRA Ophthalmology $143 2 payments
  10. Ryzumvi $108 5 payments
  11. Other $303 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

70

Median for Ophthalmology: 891

Drug cost

$32,874

Median for Ophthalmology: $68,233

Branded share of claims

55.7%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Miebo Perfluorohexyloctane/Pf Brand 27 $19,485
Tyrvaya Varenicline Tartrate Brand 12 $12,520
Fluorometholone Generic 11 $654
Ofloxacin Generic 20 $214

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TYRVAYA
  • Oyster Point Pharma, Inc. $118
$118 12 —
MIEBO
  • Bausch & Lomb Americas Inc. $86
$86 27 —
XIIDRA
  • Bausch & Lomb Americas Inc. $86
$86 — —
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $42
$42 — —
VYZULTA
  • Bausch & Lomb Americas Inc. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

84 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record